Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ECX Followed by Chemoradiation in Esophageal SCC
NCT00220129Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2002
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Royal Marsden NHS Foundation Trust. Started Nov 2002; status: completed.
02
Drugs
capecitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT00220129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220129.